CERA

About

Dr Isabel Lopez Sanchez

Head of Mitochondrial Biology and Disease

Dr Isabel Lopez Sanchez leads CERA’s mitochondrial biology and disease research, investigating the molecular mechanisms underlying vision loss in optic neuropathies such as Leber hereditary optic neuropathy (LHON) and glaucoma.

Dr Isabel Lopez Sanchez

Head of Mitochondrial Biology and Disease

BSc, PhD

Dr Isabel Lopez Sanchez is a Principal Investigator at CERA, leading research into mitochondrial biology and disease.

Her work bridges molecular biology, genetics and clinical research to understand the causes of vision loss. Trained in France, the USA and Australia, Dr Lopez Sanchez completed her PhD at the University of Western Australia and conducted postdoctoral research across Europe and the USA before establishing her independent research program at CERA.

Dr Isabel Lopez Sanchez’s research ranges from discovering new genes and proteins involved in genetic eye disease to identifying therapeutic targets for optic neuropathies such as Leber’s hereditary optic neuropathy (LHON) and glaucoma. Using human-relevant models — including post-mortem human retina and stem-cell-derived cells — she integrates molecular, epidemiological and patient-focused approaches to connect laboratory findings with real-world impact.

Her collaborative work on LHON in Australia was recognised nationally as a finalist for the 2025 Outstanding Patient Research Award (Patients Australia). She has also received multiple early-career and international research awards, including the Hitesh Peshavariya Award for Best Early Career Researcher (CERA) and a Wenner-Gren Fellowship (Sweden).

Key research questions
  • Which molecular and genetic mechanisms drive retinal ganglion cell loss in optic neuropathies such as LHON and glaucoma?
  • What new genes and proteins underlie vision loss, how do they influence mitochondrial and cellular function, and can these pathways be targeted to prevent or slow disease progression?
  • What is the true epidemiology and clinical spectrum of LHON and related mitochondrial eye diseases across populations?
  • How does mitochondrial and genetic eye disease affect individuals beyond vision, including systemic symptoms and quality of life?

Current projects

Selected publications

Key collaborators

Funding and support

Current projects

Identifying therapeutic pathways to prevent retinal ganglion cell degeneration

Investigating molecular mechanisms driving retinal ganglion cell loss in optic neuropathies such as LHON and glaucoma, with the goal of identifying molecular targets to slow or prevent neurodegeneration.

Using human models to study mitochondrial and genetic eye disease

Employing post-mortem human retina and stem-cell-derived cells to uncover molecular signatures of disease and cell resilience that can inform new therapeutic strategies.

Collaborative translational research in inherited vision loss

Working with national and international partners to study the systemic and quality-of-life impact of eye diseases and contribute to the development of gene-agnostic treatments for optic neuropathies.

Contact Dr Isabel Lopez Sanchez

Leave a direct enquiry for CERA below!

Please note: Unfortunately we are not able to provide individual medical advice over email.

General Contact Form
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.